BR0110519A - Method for inhibiting amyloid protein aggregation and imaging of amyloid deposits using aminoindan derivatives - Google Patents

Method for inhibiting amyloid protein aggregation and imaging of amyloid deposits using aminoindan derivatives

Info

Publication number
BR0110519A
BR0110519A BR0110519-1A BR0110519A BR0110519A BR 0110519 A BR0110519 A BR 0110519A BR 0110519 A BR0110519 A BR 0110519A BR 0110519 A BR0110519 A BR 0110519A
Authority
BR
Brazil
Prior art keywords
protein aggregation
amyloid
inhibiting
imaging
formula
Prior art date
Application number
BR0110519-1A
Other languages
Portuguese (pt)
Inventor
Nancy Sue Barta
Christopher Franklin Bigge
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR0110519A publication Critical patent/BR0110519A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
    • C07C229/58—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position having the nitrogen atom of at least one of the amino groups further bound to a carbon atom of a six-membered aromatic ring, e.g. N-phenyl-anthranilic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/64—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"MéTODO PARA INIBIR A AGREGAçãO DE PROTEìNAS AMILóIDES E FORMAR IMAGENS DOS DEPóSITOS DE AMILóIDES USANDO DERIVADOS DE AMINOINDANO". A presente invenção provê compostos de fórmula (I) e um método para o tratamento de doença de Alzheimer, usando um composto de fórmula (I), em que R^ 1^ e R^ 2^ incluem alquila e fenilalquila; R^ 3^ é hidrogênio ou alquila, e R~ 4~ e R~ 5~ incluem alquila, alcóxi, carboxila, alcoxicarbonila, e nitro. Também é provido um método para inibir a agregação de proteínas amilóides usando o composto de fórmula (I) e um método para a formação de imagem dos depósitos de amilóides usando os compostos de fórmula (I)."METHOD FOR INHIBITING AMILOID PROTEIN AGGREGATION AND FORMING IMAGES OF AMYLOID DEPOSITS USING AMINOINDANO DERIVATIVES". The present invention provides compounds of formula (I) and a method for the treatment of Alzheimer's disease using a compound of formula (I), wherein R 1 and R 2 include alkyl and phenylalkyl; R3 is hydrogen or alkyl, and R4 and R5 include alkyl, alkoxy, carboxyl, alkoxycarbonyl, and nitro. Also provided is a method for inhibiting amyloid protein aggregation using the compound of formula (I) and a method for imaging amyloid deposits using the compounds of formula (I).

BR0110519-1A 2000-05-04 2001-04-25 Method for inhibiting amyloid protein aggregation and imaging of amyloid deposits using aminoindan derivatives BR0110519A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20199600P 2000-05-04 2000-05-04
PCT/US2001/013254 WO2001083425A1 (en) 2000-05-04 2001-04-25 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives

Publications (1)

Publication Number Publication Date
BR0110519A true BR0110519A (en) 2003-04-08

Family

ID=22748150

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0110519-1A BR0110519A (en) 2000-05-04 2001-04-25 Method for inhibiting amyloid protein aggregation and imaging of amyloid deposits using aminoindan derivatives

Country Status (11)

Country Link
US (1) US6949575B2 (en)
EP (1) EP1284958B1 (en)
JP (1) JP2003531883A (en)
AT (1) ATE304522T1 (en)
AU (1) AU2001255646A1 (en)
BR (1) BR0110519A (en)
CA (1) CA2405611A1 (en)
DE (1) DE60113407T2 (en)
ES (1) ES2248315T3 (en)
MX (1) MXPA02009948A (en)
WO (1) WO2001083425A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005027939A1 (en) * 2003-08-21 2005-03-31 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
EP2121633A2 (en) 2007-02-12 2009-11-25 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
JP2009084254A (en) * 2007-10-03 2009-04-23 Sumitomo Chemical Co Ltd PHARMACEUTICAL COMPOSITION FOR INHIBITING ACCUMULATION OF AMYLOID beta PROTEIN
WO2009079566A2 (en) 2007-12-18 2009-06-25 Acumen Pharmaceuticals, Inc. Novel addl receptor polypeptides, polynucleotides and host cells for recombinant production
US10196700B2 (en) 2009-03-24 2019-02-05 University Of Chicago Multivolume devices, kits and related methods for quantification and detection of nucleic acids and other analytes
US9464319B2 (en) 2009-03-24 2016-10-11 California Institute Of Technology Multivolume devices, kits and related methods for quantification of nucleic acids and other analytes
US9447461B2 (en) 2009-03-24 2016-09-20 California Institute Of Technology Analysis devices, kits, and related methods for digital quantification of nucleic acids and other analytes
CN104722342B (en) 2009-03-24 2017-01-11 芝加哥大学 Slip chip device and method
WO2013159116A1 (en) 2012-04-20 2013-10-24 University Of Chicago Fluidic devices for biospecimen preservation
US9822356B2 (en) 2012-04-20 2017-11-21 California Institute Of Technology Fluidic devices and systems for sample preparation or autonomous analysis
US9803237B2 (en) 2012-04-24 2017-10-31 California Institute Of Technology Slip-induced compartmentalization
PL2915804T3 (en) * 2012-10-31 2019-09-30 Fujifilm Toyama Chemical Co., Ltd. Novel amine derivative or salt thereof as tnf alpha inhibitors
KR20180052611A (en) * 2015-08-18 2018-05-18 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Nitroxide-containing amyloid binding agents for imaging and therapeutic applications
WO2018111805A1 (en) * 2016-12-13 2018-06-21 St. Jude Children's Research Hospital Tetrahydroquinoline-based bromodomain inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816456A (en) * 1986-10-01 1989-03-28 Summers William K Administration of monoamine acridines in cholinergic neuronal deficit states
GB8707123D0 (en) * 1987-03-25 1987-04-29 Pfizer Ltd Antiarrhythmic agents
US5280032A (en) * 1989-02-14 1994-01-18 Toyama Chemical Co., Ltd. 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same
EP0535496A1 (en) * 1991-09-25 1993-04-07 Hoechst-Roussel Pharmaceuticals Incorporated (1-Indanon-2yl)methylpiperidines, intermediates and a process for their preparation and their use as medicaments
IL99759A (en) * 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
NZ248573A (en) * 1992-09-10 1996-02-27 Lilly Co Eli 5-arylmethyl (and methylidene) thiazolidin-4-one derivatives; their preparation and pharmaceutical compositions
WO1997026919A2 (en) * 1996-01-24 1997-07-31 Warner-Lambert Company Method of imaging amyloid deposits
SE9802360D0 (en) * 1998-07-01 1998-07-01 Wikstroem Hakan Vilhelm New 2-aminothiazole-fused 2-amino indans and 2-aminotetralins ((basic) -N-substituted and (basic) -N, N-disubstituted derivatives of 2,6-diamino-thiazolo (4,5-f) indan and 2 , 7-di-amino-thiazolo (4,5-g) tetralin

Also Published As

Publication number Publication date
US20030220382A1 (en) 2003-11-27
DE60113407D1 (en) 2005-10-20
EP1284958B1 (en) 2005-09-14
WO2001083425A1 (en) 2001-11-08
AU2001255646A1 (en) 2001-11-12
JP2003531883A (en) 2003-10-28
EP1284958A1 (en) 2003-02-26
ATE304522T1 (en) 2005-09-15
CA2405611A1 (en) 2001-11-08
US6949575B2 (en) 2005-09-27
MXPA02009948A (en) 2003-02-12
ES2248315T3 (en) 2006-03-16
DE60113407T2 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
BR0110519A (en) Method for inhibiting amyloid protein aggregation and imaging of amyloid deposits using aminoindan derivatives
BRPI0407618A (en) cycloalkyl-substituted amino thiazole derivatives containing n and pharmaceutical compositions for inhibiting cell proliferation and methods for their use
UY26813A1 (en) COMPOUNDS TO TREAT ALZHEIMER'S DISEASE
BR0011446A (en) Inhibition method of amyloid protein aggregation and imaging of amyloid deposits using isoindoline derivatives
BR0109851A (en) Compound, method for producing the same or a salt thereof, prodrug, pharmaceutical composition, method for inhibiting tyrosine kinase, method for preventing or treating cancer, and use of a compound or salt or prodrug thereof
BR0210391A (en) Compound, methods of treating a patient who has or prevent a patient from contracting a disease or condition and preparing a compound, and, using a compound
BRPI0409624A (en) Benzamide 2-hydroxy-3-diaminoalkanes
BRPI0515628A (en) 2-morpholine-4-pyrimidone compound
BRPI0516904A (en) process for the preparation of a 2-ethylaminopyridine derivative and compound
BR0111980A (en) Substituted amine, protected compound, methods for treating a patient having or preventing a patient from contracting a disease or condition, inhibiting beta-secretase activity, inhibiting cleavage of amyloid precursor protein (app), inhibiting Production of the beta amyloid peptide (a beta) in a cell, to inhibit beta0amyloid plaque production in an animal, and to treat or prevent a disease comprising beta-amyloid deposits in the brain, composition method for producing a beta-secretase complex , assembly, and use of substituted amine
DE602004007808D1 (en) NEW GAMMA SECRETASE INHIBITORS
BR0212787A (en) Pharmaceutically acceptable compound or salt thereof, methods of treating or preventing disease and preparing a compound, use of a compound or salt, and pharmaceutical composition
DE69310501D1 (en) CHINOLYLBENZOFURAN DERIVATIVES AS LEUKOTRIA ANTAGONISTS
BR0210874A (en) Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation and methods for their use
BR0211118A (en) Compound, methods for treating or preventing disease and for making a compound, intermediate, and use of a compound or salt
BRPI0414177A (en) gyrase inhibitors
BRPI0407695A (en) compounds, process for preparing a compound, pharmaceutical compositions comprising the compound, use of the compounds and treatment method for type 2 diabetes
BRPI0510221A (en) aryl ketone compound, composition, unit dosage form, use of the composition and method for preparing a composition
BR0113590A (en) 7-oxopyridopyrimidines
BRPI0411285A (en) compound, process for preparing a compound pharmaceutical formulation, use of a compound, and method of preventing or treating disorders
BR0011728A (en) Method of inhibiting aggregation of amyloid protein and image of amyloid deposits
BR0215067A (en) Antiviral Pyridoquinoxalines
BRPI0414241A (en) compound, pharmaceutical composition, methods for activating 5-ht1f receptors in a mammal, inhibiting neuronal protein extravasation in a mammal, and treating or preventing migraine in a mammal, and, use of a compound
BR0011441A (en) Rhodanine derivatives for use in a method of inhibiting amyloid protein aggregation and imaging amyloid deposits
BR0211121A (en) Compound, methods for treating or preventing disease and for making a compound, intermediate, and use of a compound or salt

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO DA RPI 2016 DE 25/08/2009.